UC Blue Ash alum shares her story as a dreamer
Karen Rosen-Guevara celebrates after graduating from UC Blue Ash.
University of Cincinnati Blue Ash College alumna Karen Rosen-Guevara is proud to be a Dreamer. That is why she was so excited to learn that The Cincinnati Enquirer chose to publish an op-ed she submitted about being part of the Deferred Action for Childhood Arrivals (DACA).
“I was speechless, amazed,” Rosen-Guevara said. “I never thought that my story would be read by hundreds of other people in my own community. It was such a great opportunity and I enjoyed every second of it.”
The op-ed was based on an English paper Rosen-Guevara wrote while at UC Blue Ash titled ‘This I Believe.’ She received a lot of positive feedback on the piece and was encouraged to submit it to The Activist, the UC Blue Ash student news site. She also shared it with Define American, an organization that uses media and storytelling to shift the narrative around immigrants in the U.S.
The op-ed appeared on June 26, shortly after the recent Supreme Court ruling that upheld DACA. Rosen-Guevara tells her story of moving with her parents to the U.S. from El Salvador at a very young age. Her parents’ goal in making the move was to provide her with a better future. Although she initially struggled in school while learning English, they encouraged her to work hard and pursue a college education.
“They wanted me to succeed in school and have the career of my choice once I graduated from college,” Rosen-Guevara shared in the op-ed. “They never placed a limit on my dreams, and they always inspired me to try my best.”
Rosen-Guevara graduated from UC Blue Ash, and is currently a student in UC’s College of Arts & Sciences, where she is majoring in Spanish and political science.
She says her future in America is still a little uncertain, even after the Supreme Court ruling, but she remains focused on her goals and on making her parents proud.
“I believe that one day I’ll complete my journey and that everything my parents did for me will be worth it,” Rosen-Guevara states in the op-ed. “I aspire to keep my head high, my heart pure and my roots proud. I am DACA, and I am a Dreamer.”
About UC Blue Ash College
UC Blue Ash College is a regional college within the University of Cincinnati. It offers one of the best values in higher education with access to a nationally recognized UC education in more than 50 degree and certificate programs, as well as tuition that is about half of most colleges and universities. The college is located on a scenic 135-acre wooded campus in the heart of Blue Ash, Ohio. To learn more, call 513-745-5600, visit us online, like us on Facebook or follow us on Twitter and Instagram.
Related Stories
Make Hoxworth Blood Center’s special holiday events part of your family celebrations this December
December 12, 2025
This December, Hoxworth Blood Center, University of Cincinnati, is inviting families across Greater Cincinnati to add something truly meaningful to their holiday traditions: giving the gift of life. With festive community events, beloved local partners and special thank-you gifts for donors, Hoxworth is making it easier, and more heartwarming than ever, to roll up your sleeves and help save lives close to home.
University of Cincinnati college is piloting a program to serve alumni of foster and kinship care
December 12, 2025
In 2025 the Ohio Reach Postsecondary designation was awarded to UC's College of Education, Criminal Justice, Human Services, and Information Technology (CECH) as part of the program's third cohort. The program recognizes and supports higher education institutions that have worked to make their campuses welcoming and accessible for students with a history in foster or kinship care. CECH will run a pilot program called Anchor Point aimed at wide-scale implementation across the campus in Fall 2026.
New combination treatment improves multiple myeloma outcomes
December 11, 2025
The University of Cincinnati Cancer Center's Ed Faber, DO, provided commentary to Medscape on the COBRA study that found the combination of carfilzomib combined with lenalidomide and dexamethasone (KRd) shows significantly greater efficacy than the previous standard of care.